4
Changes in Ownership
Serina Therapeutics, Inc. Filed Acc 0001301120-26-000006
Chief Scientific Officer sold 4,000 shares at an average $3.04 ($12,140)
- Chief Scientific Officer acquired 4,000 shares (option exercise)
- Traded under a Rule 10b5-1 plan
From the SEC's structured data for this filing
Trades in this filing
Moreadith Randall · Chief Scientific Officer
Table I: Non-derivative
4 lines| Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|
| 2026-01-20 | Exercise or conversion : show line 1 in the form 10b5-1 | +2,000 | $0.06 | $120 | 2,000 | D |
| 2026-01-20 | Sale : show line 2 in the form 10b5-1 | −2,000 | $3.07 | $6,140 | 0 | D |
| 2026-01-21 | Exercise or conversion : show line 3 in the form 10b5-1 | +2,000 | $0.06 | $120 | 2,000 | D |
| 2026-01-21 | Sale : show line 4 in the form 10b5-1 | −2,000 | $3.00 | $6,000 | 0 | D |
| Open-market sales · 4,000 sh · avg $3.04 · $12,140 | ||||||
Table II: Derivative
2 lines| Date | Transaction | Shares | Owned after | D/I |
|---|---|---|---|---|
| 2026-01-20 | Exercise or conversion : show line 5 in the form 10b5-1 Stock Option (right to buy) | −2,000 | 330,686 | D |
| 2026-01-21 | Exercise or conversion : show line 6 in the form 10b5-1 Stock Option (right to buy) | −2,000 | 328,686 | D |
Loading xslF345X05/wk-form4_1769041031.xml…